SCHEMBL4978776

SCHEMBL4978776

Cc1ccc(Nc2nccc(NCc3ccc4c(c3)nc(NCc3ccccc3F)n4C)n2)cc1S(N)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.47
▸ TP53 P04637 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CSF1R P07333 5/20 0.40
▸ TYK2 P29597 4/20 0.40
▸ ULK2 Q8IYT8 1/20 0.40
▸ TBK1 Q9UHD2 1/20 0.40
▸ KDR P35968 3/20 0.39
▸ AURKA O14965 3/20 0.39
▸ MAP4K4 O95819 3/20 0.39
▸ MAPK8 P45983 3/20 0.39
▸ AURKB Q96GD4 3/20 0.39
▸ JAK2 O60674 3/20 0.39
▸ JAK3 P52333 3/20 0.39
▸ LYN P07948 3/20 0.39
▸ SYK P43405 3/20 0.39
▸ PTK2 Q05397 2/20 0.39
▸ PLK4 O00444 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4978749 0.99 BTK (0.46) BTKTP53POLBGAASMN1; SMN2
SCHEMBL4976707 0.91 BTK (0.51) BTKSMN1; SMN2CSF1RTYK2ULK2
Hydrochloric Acid SCHEMBL4976684 0.90 BTK (0.50) BTKSMN1; SMN2CSF1RTYK2ULK2
SCHEMBL4981895 0.90 BTK (0.50) BTKCSF1RTYK2ULK2TBK1
SCHEMBL4976729 0.90 BTK (0.48) BTKCSF1RTYK2ULK2TBK1
Hydrochloric Acid SCHEMBL4980298 0.89 BTK (0.49) BTKCSF1RTYK2ULK2TBK1
SCHEMBL4983399 0.89 SMN1; SMN2 (0.46) TP53POLBGAASMN1; SMN2CSF1R
Hydrochloric Acid SCHEMBL4980442 0.89 BTK (0.47) BTKCSF1RTYK2ULK2TBK1
Hydrochloric Acid SCHEMBL4979958 0.89 SMN1; SMN2 (0.46) TP53POLBGAASMN1; SMN2CSF1R
SCHEMBL4980837 0.87 BTK (0.50) BTKSMN1; SMN2CSF1RTYK2ULK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 — — US claimed
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 — — US claimed
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 — — US disclosed
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors TIE1, TEK, KDR BTK 895/4885TP53 576/4885POLB 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback